ABSTRACT
Microneedle Array Patches (MAPs) are an emerging dosage form that creates transient micron-sized disruptions in the outermost physical skin barrier, the stratum corneum, to facilitate delivery of active pharmaceutical ingredients to the underlying tissue. Numerous MAP products are proposed and there is significant clinical potential in priority areas such as vaccination. However, since their inception scientists have hypothesized about the risk of a clinically significant MAP-induced infection. Safety data from two major Phase 3 clinical trials involving hundreds of participants, who in total received tens of thousands of MAP applications, does not identify any clinically significant infections. However, the incumbent data set is not extensive enough to make definitive generalizable conclusions. A comprehensive assessment of the infection risk is therefore advised for MAP products, and this should be informed by clinical and pre-clinical data, theoretical analysis and informed opinions. In this article, a group of key stakeholders identify some of the key product- and patient-specific factors that may contribute to the risk of infection from a MAP product and provide expert opinions in the context of guidance from regulatory authorities. Considerations that are particularly pertinent to the MAP dosage form include the specifications of the finished product (e.g. microbial specification), it's design features, the setting for administration, the skill of the administrator, the anatomical application site, the target population and the clinical context. These factors, and others discussed in this article, provide a platform for the development of MAP risk assessments and a stimulus for early and open dialogue between developers, regulatory authorities and other key stakeholders, to expedite and promote development of safe and effective MAP products.
Subject(s)
Drug Delivery Systems , Skin , Humans , Administration, Cutaneous , Epidermis , Needles , Pharmaceutical Preparations , Risk Assessment , Clinical Trials, Phase III as TopicABSTRACT
A trivalent influenza split vaccine was formulated at high concentration for coating on the transdermal microneedle system. Monovalent vaccine bulks of three influenza strains, two influenza A strains, and one B strain were diafiltrated, concentrated, and lyophilized. The lyophilized powder of each vaccine strain was separately reconstituted and subsequently combined into a coating formulation of high concentration trivalent vaccine. The formulation process converted the monovalent vaccine bulks with low hemagglutinin (HA) concentrations 0.1 mg/mL into a viscous, emulsion containing HA at ~50 mg/mL. This physically stable emulsion demonstrated viscosity 1 poise and 30° contact angle for effective, homogeneous coating on each microneedle. Evaluation of the vaccine antigen HA by SRID and SDS-PAGE/Western blot showed that HA remained stable throughout the vaccine transdermal microneedle system manufacturing process and 1-year ambient storage (25°C). Anti-influenza antibody responses were evaluated by ELISA and hemagglutination inhibition (HAI) assay after primary and booster immunization with the vaccine-coated transdermal microneedle systems at either 25-µg or 40-µg total HA. The results showed the induction of serum anti-influenza IgG and anti-HA neutralizing antibodies after primary immunization and significant titer rises after booster immunization for both doses, indicating the dry-coated trivalent vaccine delivered by transdermal microneedle system elicited both primary and recall antibody responses against all three antigen strains. The study demonstrates that the transdermal microneedle system provides an attractive alternative for influenza vaccine delivery with key advantages such as preservative-free and room-temperature storage.
Subject(s)
Drug Delivery Systems/instrumentation , Influenza A Virus, H1N1 Subtype/immunology , Influenza Vaccines/administration & dosage , Influenza Vaccines/chemical synthesis , Needles , Transdermal Patch , Administration, Cutaneous , Animals , Drug Delivery Systems/methods , Female , Guinea Pigs , Vaccination/instrumentation , Vaccination/methodsABSTRACT
The purpose of this study was to develop models to predict the severity of pedestrian accidents on rural roads of Guilan, Iran. Therefore, the probability of occurrence of any type of accidents was measured using the accident data from March 2014 to March 2019. Eleven independent variables affecting the severity of pedestrian accidents as well as statistical analysis such as the frequency analysis, Friedman test and factor analysis, and modeling including multiple logistic regression and artificial neural networks using multi-layer perceptron (MLP) and radius basis function (RBF) have been used. Results of modeling and analysis of pedestrian accidents in different methods showed each of the methods depending on their function investigated the severity of accidents with different point of view and had different results. As a result, putting the output results together, the best measures can be suggested to increase the safety of pedestrians on the rural roads of Guilan.
Subject(s)
Accidents, Traffic , Death , Models, Statistical , Pedestrians , Wounds and Injuries , Accidents, Traffic/trends , Factor Analysis, Statistical , Female , Forecasting , Humans , Iran/epidemiology , Logistic Models , Male , Rural Population , Wounds and Injuries/epidemiologyABSTRACT
M207 is an investigational intracutaneous microneedle therapeutic system for nonoral zolmitriptan delivery. In a Phase I trial, M207 provided faster absorption with a higher 2 h exposure than oral zolmitriptan. In the pivotal trial evaluating efficacy, tolerability and safety in moderate-to-severe migraine attacks, M207 3.8 mg was superior to placebo in providing freedom from headache pain (42 vs 14%) and freedom from most bothersome symptom (68 vs 43%) 2 h post-dose. Treatment-emergent adverse events were mild and transient and most commonly concerned the application site. In post hoc analyses: pain freedom was sustained in approximately 1/3 of patients; efficacy was observed in migraine headaches that are typically more difficult to treat.
Subject(s)
Migraine Disorders , Tryptamines , Double-Blind Method , Humans , Migraine Disorders/drug therapy , Oxazolidinones , Treatment Outcome , Tryptamines/adverse effectsABSTRACT
Franz cell studies, utilizing different human skin and an artificial membrane, evaluating the influence of skin model on permeation of zolmitriptan coated on an array of titanium microprojections, were evaluated. Full thickness and dermatomed ex vivo human skin, as well as a synthetic hydrophobic membrane (Strat-M®), were assessed. It was found that the choice of model demonstrated different absorption kinetics for the permeation of zolmitriptan. For the synthetic membrane only 11% of the zolmitriptan coated dose permeated into the receptor media, whilst for the dermatomed skin 85% permeated into the receptor. The permeation of zolmitriptan through full thickness skin had a significantly different absorption profile and time to maximum flux in comparison to the dermatomed skin and synthetic model. On the basis of these results dermatomed skin may be a better estimate of in vivo performance of drug-coated metallic microprojections.
ABSTRACT
Adhesive Dermally Applied Microarray (ADAM) is a new drug-delivery system that uses microprojections (340-µm long) for intracutaneous drug self-administration. We formulated zolmitriptan, a well-accepted and commonly used migraine medication, for administration using ADAM. In vivo studies were conducted in female prepubescent Yorkshire pigs using ADAM 1.9-mg zolmitriptan applied to the inner thigh and left in place for 1 h. Pharmacokinetic studies showed that the ADAM 1.9-mg zolmitriptan was delivered with high efficiency (85%) and high absolute bioavailability (77%). Furthermore, in vivo evaluation showed a rapid systemic absorption with a median Tmax of 15 min. Skin biopsies of the treatment sites showed a mean depth of microprojection penetration of 105.4 ± 3.6 µm. Mass spectrometry imaging showed that the zolmitriptan after 1 h of patch wear time was predominantly localized to the dermis. ADAM zolmitriptan was well tolerated with a transient mild-to-moderate erythema response. The findings in these studies, particularly the rapid zolmitriptan absorption profile after intracutaneous administration, provided validation to advance ADAM zolmitriptan development.
Subject(s)
Drug Delivery Systems/instrumentation , Oxazolidinones/administration & dosage , Oxazolidinones/pharmacokinetics , Serotonin 5-HT1 Receptor Agonists/administration & dosage , Serotonin 5-HT1 Receptor Agonists/pharmacokinetics , Transdermal Patch , Tryptamines/administration & dosage , Tryptamines/pharmacokinetics , Administration, Cutaneous , Animals , Biological Availability , Equipment Design , Female , Migraine Disorders/drug therapy , Oxazolidinones/adverse effects , Serotonin 5-HT1 Receptor Agonists/adverse effects , Skin/drug effects , Skin/metabolism , Skin Absorption , Swine , Tryptamines/adverse effectsABSTRACT
Adhesive Dermally-Applied Microarray (ADAM) is a device for intracutaneous drug administration consisting of a 3 cm2 disposable array of drug-coated titanium microprojections on an adhesive backing. It is applied using a low cost, reusable, handheld applicator. Microprojections penetrate the stratum corneum, delivering drug proximal to capillaries with limited likelihood of pain. The pharmacokinetics of zolmitriptan delivery using ADAM was evaluated in 20 healthy volunteers. Median tmax was <20 min, comparable to subcutaneous sumatriptan. Absorption was faster than for oral zolmitriptan, with higher exposure in the first 2 h. Most adverse events were consistent with those seen in previous triptan trials. Application site reactions were generally mild and resolved within 24 h. ADAM zolmitriptan shows a promising pharmacokinetic profile for migraine treatment.
Subject(s)
Drug Delivery Systems , Migraine Disorders/drug therapy , Oxazolidinones/administration & dosage , Oxazolidinones/pharmacokinetics , Tryptamines/administration & dosage , Tryptamines/pharmacokinetics , Administration, Cutaneous , Adult , Cross-Over Studies , Drug Delivery Systems/instrumentation , Drug Delivery Systems/methods , Female , Humans , Male , Oxazolidinones/adverse effects , Oxazolidinones/blood , Pain Management/methods , Skin Physiological Phenomena/drug effects , Tryptamines/adverse effects , Tryptamines/bloodABSTRACT
This study evaluated the feasibility of coating formulated recombinant human growth hormone (rhGH) on a titanium microneedle transdermal delivery system, Zosano Pharma (ZP)-hGH, and assessed preclinical patch delivery performance. Formulation rheology and surface activity were assessed by viscometry and contact angle measurement. rhGH liquid formulation was coated onto titanium microneedles by dip-coating and drying. The stability of coated rhGH was determined by size exclusion chromatography-high performance liquid chromatography (SEC-HPLC). Preclinical delivery and pharmacokinetic studies were conducted in female hairless guinea pigs (HGP) using rhGH coated microneedle patches at 0.5 and 1 mg doses and compared to Norditropin® a commercially approved rhGH subcutaneous injection. Studies demonstrated successful rhGH formulation development and coating on microneedle arrays. The ZP-hGH patches remained stable at 40 °C for six months with no significant change in % aggregates. Pharmacokinetic studies showed that the rhGH-coated microneedle patches, delivered with high efficiency and the doses delivered indicated linearity with average Tmax of 30 min. The absolute bioavailability of the microneedle rhGH patches was similar to subcutaneous Norditropin® injections. These results suggest that ZP-transdermal microneedle patch delivery of rhGH is feasible and may offer an effective and patient-friendly alternative to currently marketed rhGH injectables.
ABSTRACT
PURPOSE: To evaluate the feasibility of coating formulated recombinant human erythropoietin alfa (EPO) on a titanium microneedle transdermal delivery system, ZP-EPO, and assess preclinical patch delivery performance. METHODS: Formulation rheology and surface activity were assessed by viscometry and contact angle measurement. EPO liquid formulation was coated onto titanium microneedles by dip-coating and drying. Stability of coated EPO was assessed by SEC-HPLC, CZE and potency assay. Preclinical in vivo delivery and pharmacokinetic studies were conducted in rats with EPO-coated microneedle patches and compared to subcutaneous EPO injection. RESULTS: Studies demonstrated successful EPO formulation development and coating on microneedle arrays. ZP-EPO patch was stable at 25°C for at least 3 months with no significant change in % aggregates, isoforms, or potency. Preclinical studies in rats showed the ZP-EPO microneedle patches, coated with 750 IU to 22,000 IU, delivered with high efficiency (75-90%) with a linear dose response. PK profile was similar to subcutaneous injection of commercial EPO. CONCLUSIONS: Results suggest transdermal microneedle patch delivery of EPO is feasible and may offer an efficient, dose-adjustable, patient-friendly alternative to current intravenous or subcutaneous routes of administration.
Subject(s)
Coated Materials, Biocompatible , Drug Delivery Systems/instrumentation , Erythropoietin/administration & dosage , Hematinics/administration & dosage , Needles , Administration, Cutaneous , Animals , Chemistry, Pharmaceutical , Chromatography, Gel , Chromatography, High Pressure Liquid , Drug Compounding , Drug Stability , Epoetin Alfa , Equipment Design , Erythropoietin/blood , Erythropoietin/chemistry , Erythropoietin/pharmacokinetics , Feasibility Studies , Hematinics/blood , Hematinics/chemistry , Hematinics/pharmacokinetics , Humans , Injections, Subcutaneous , Male , Miniaturization , Rats , Rats, Sprague-Dawley , Recombinant Proteins/administration & dosage , Recombinant Proteins/blood , Recombinant Proteins/chemistry , Recombinant Proteins/pharmacokinetics , Rheology , Skin/metabolism , Skin Absorption , Technology, Pharmaceutical/methods , Titanium , ViscosityABSTRACT
PURPOSE: Assess formulation parameters to enable >24-h continuous accurate and uniform coating of PTH(1-34) on a novel transdermal microprojection array delivery system. METHODS: Surface activity and rheology of the liquid formulation was determined by contact angle measurement and cone-plate viscometry. The formulation's delivery performance was assessed in vivo using the hairless guinea pig model. Peptide gelation was investigated by rheological and viscoelastic behavior changes. RESULTS: Accurate and uniform coating was achieved by formulating the liquid formulation to a preferred contact angle range of 30-60 degrees with a surfactant and by establishing a Newtonian fluid (defined as a fluid maintaining a constant viscosity with shear rate and time) with a viscosity of > or =20 cps via adjusting the peptide concentration and using an appropriate acidic counterion. A non-volatile acidic counterion was found critical to compensate for the loss of the volatile acetate counterion to maintain the peptide formulation's solubility upon rehydration in the skin. Finally, the 15.5% w/w PTH(1-34) concentration was found to be the most physically stable formulation (delayed gelation) in the roll-coating reservoir. With a properly designed coating reservoir for shear force reduction, the liquid formulation could last for more than 24 h without gelation. CONCLUSIONS: The study successfully offered scientific rationales for developing an optimal liquid formulation for a novel titanium microprojection array coating process. The resultant formulation has an enduring physical stability (>24 h) in the coating reservoir and maintained good in vivo dissolution performance.
Subject(s)
Coated Materials, Biocompatible/administration & dosage , Coated Materials, Biocompatible/chemistry , Drug Delivery Systems/instrumentation , Parathyroid Hormone/administration & dosage , Parathyroid Hormone/chemistry , Administration, Cutaneous , Animals , Chemistry, Pharmaceutical , Drug Delivery Systems/methods , Guinea Pigs , Skin Absorption/drug effects , Skin Absorption/physiology , Surface Properties/drug effectsABSTRACT
Terminal sterilization via gamma-irradiation or e-beam and aseptic processing were evaluated as a means to manufacture the sterile product of parathyroid hormone 1-34 coated on a novel transdermal microprojection delivery system. The main difference of the two methods is the inclusion and exclusion of the coated formulation for irradiation during terminal sterilization and aseptic processing, respectively. Both gamma-irradiation and e-beam of the final product resulted in increased PTH(1-34) oxidation, which could be reduced by lowering the irradiation dose or the irradiation temperature. Minimizing moisture and oxygen levels inside the primary packaging could effectively limit PTH oxidation to < 2% initially, but the stability continued deteriorating to fall below the purity specification over 3-month storage. Aseptic processing has its own challenge as one of the device components, acrylic-based adhesive, was found to be incompatible with the peptide due to volatile compound(s) released from the irradiated adhesive. Although the nature of the volatile compounds was not fully understood, we developed a screening method capable of rapidly and effectively identifying an alternate adhesive. This study proved that aseptic processing is the choice of the sterile manufacturing approach and wouldn't compromise the target of achieving > or = 2-year, ambient-temperature storage stability.
Subject(s)
Drug Delivery Systems/instrumentation , Gamma Rays , Parathyroid Hormone/administration & dosage , Parathyroid Hormone/chemistry , Sterilization/methods , Adhesiveness , Drug Stability , Drug Storage , Equipment Design , Oxygen/chemistryABSTRACT
PURPOSE: This study assessed conditions necessary for at least a 2-year, ambient temperature storage stability of the peptide parathyroid hormone 1-34, or PTH(1-34), coated on a novel transdermal microprojection delivery system, or ZP-PTH. METHODS: Liquid coating characterization of high concentration PTH(1-34) formulations (>20% w/w) was assessed by viscosity and contact angle measurements along with RP-HPLC and SEC-HPLC. Solid-state coating morphology of PTH(1-34) on microprojection arrays was determined by SEM, and stability on storage was assessed after dissolution and testing with stability indicating assays. Internal vapor analysis was performed to detect and quantify volatile organics released by patch components into the headspace inside the final package. RESULTS: Aggregation and oxidation were the primary degradation mechanisms for solid-state PTH(1-34) in this transdermal delivery system. Although these two degradation pathways can be retarded by appropriate stabilizers and use of foil pouch packaging (nitrogen purged and desiccant), the solid-state drug formulation's compatibility with patch components, particularly the plastic retainer ring, surprisingly dictated PTH(1-34) stability. Internal vapor analysis demonstrated that PTH(1-34) was particularly vulnerable to vapors such as moisture, oxygen, and outgassed formaldehyde, and each of these volatiles played a unique and significant role in PTH(1-34)'s degradation mechanism. CONCLUSIONS: Identifying degradation mechanisms of volatile compounds on solid-state PTH(1-34) peptide stability allowed for the rationale for selection of final formulation, system components and packaging conditions. A >2-yr, ambient temperature storage stability was demonstrated for solid-state drug coated on a novel transdermal microprojection delivery system. This system was successfully tested in a Phase 2 clinical trial for the treatment of post-menopausal women with osteoporosis.
Subject(s)
Drug Delivery Systems , Drug Stability , Drug Storage , Parathyroid Hormone/chemistry , Water/chemistry , Administration, Cutaneous , Cell Line , Chromatography, High Pressure Liquid , Drug Delivery Systems/methods , Female , Humans , Microscopy, Electron, Scanning , Oxidation-Reduction , Parathyroid Hormone/metabolism , Surface PropertiesABSTRACT
The purpose of this study was to develop a hepatitis-B surface antigen (HBsAg) dry powder vaccine formulation suitable for epidermal powder immunization (EPI) via an efficient, scalable powder-formation process. Several HBsAg dry powder formulations were prepared using four different powder-formation methods: freeze-drying/compress/grind/sieve (FD/C/G/S), spray-drying (SD), agarose beads, and spray freeze-drying (SFD). Powder properties and physical stability were determined using particle size analysis, tap density measurement, scanning electron microscopy, optical microscopy, and moisture content analysis. Physical, chemical and biochemical stability of HBsAg was determined by dynamic light scattering, an enzyme immune assay, and immunogenicity in a mouse or hairless guinea pig model. Out of the four powder-formation methods evaluated SFD outperformed other methods in the following considerations: good process efficiency, flexible scalability, and desirable particle characteristics for skin penetration. The stress posed by SFD appeared to be mild as HBsAg in the dry form retained its potency and immunogenicity. Notably, the mechanism of fast freezing by SFD actually promoted the preservation of HBsAg nanoparticle size, in good correlation with long-term biochemical stability. Among several formulations screened, the formulation containing 10 microg HBsAg in 1-mg powder with a tertiary mixture of trehalose, mannitol, and dextran, exhibited excellent overall stability performance. In conclusion, HBsAg dry powder formulations suitable for EPI were successfully prepared using SFD. Further, a systematic formulation development strategy allowed the development and optimization of an HBsAg dry powder formulation, demonstrating excellent long-term physical, biochemical, and immunological stability.
Subject(s)
Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/chemistry , Technology, Pharmaceutical/methods , Administration, Cutaneous , Animals , Disaccharides/chemistry , Drug Stability , Excipients/chemistry , Female , Guinea Pigs , Hepatitis B Surface Antigens/genetics , Hepatitis B Vaccines/administration & dosage , Hepatitis B Vaccines/immunology , Immunization/methods , Immunoenzyme Techniques/methods , Injections, Intramuscular , Lysine/chemistry , Mice , Mice, Inbred BALB C , Microscopy, Electron, Scanning , Microspheres , Nanoparticles/chemistry , Particle Size , Poloxamer/chemistry , Powders , Sepharose/chemistryABSTRACT
The purpose of this study was to develop a spray-freeze-drying (SFD) process for preparing an influenza vaccine dry powder formulation suitable for epidermal powder immunization. After preformulation of two types of flu vaccines, their dry-powder formulations were prepared by SFD. Powder properties and physical stability were determined using particle size analysis, tap density measurement, scanning electron microscopy, optical microscopy, and moisture content analysis. Chemical and biochemical stability of vaccine antigens was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, single radial immunodiffusion assay, and in vivo immunogenicity in a mouse model. We demonstrated that SFD could produce high-density particles-a critical parameter for effective skin penetration. From the stability perspective, the stress posed by SFD was mild because the antigen in the dry powder retained its stability, potency, and immunogenicity. Among several formulations screened, we noted that formulation composition has a significant role in the powder's long-term physical and biochemical stability. One formulation, in particular, containing sub-unit vaccine (45 microg of antigen in 1 mg of powder) with a tertiary mixture of trehalose, mannitol, and dextran, exhibited excellent overall stability, including acceptable biochemical stability after being exposed to a highly humid environment. After all, we have not only demonstrated the suitability of SFD to prepare powders for epidermal powder immunization but also developed a systematic formulation development strategy that allowed the optimization of an influenza vaccine dry powder formulation. More important, this study led to the selection of a formulation system that had been successfully tested in a human clinical study.
Subject(s)
Influenza Vaccines/chemistry , Aerosols , Animals , Chemistry, Pharmaceutical , Drug Evaluation, Preclinical/methods , Drug Stability , Female , Freeze Drying/methods , Humidity/adverse effects , Influenza Vaccines/administration & dosage , Influenza Vaccines/standards , Mice , Mice, Inbred BALB C , PowdersABSTRACT
Desmopressin is a synthetic peptide hormone chiefly used for treatment of enuresis in young children. It is available in injectable, intranasal, and oral formulations. While administration by injection is poorly suited for routine use in young children, intranasal and oral administration result in low and variable bioavailability. This study therefore explored the feasibility of administering desmopressin transdermally using Macroflux technology, which uses a microneedle array to overcome the skin barrier. The tips of microneedles in 2-cm2 arrays were covered with a solid coating of various amounts of desmopressin and applied to the skin of hairless guinea pigs for 5 or 15 min. Pharmacologically relevant amounts of desmopressin were delivered after 5 min. Bioavailability was as high as 85% and showed acceptable variability (30%). Immunoreactive serum desmopressin reached peak levels after a Tmax of 60 min. Elimination kinetics for serum desmopressin was similar after transdermal and intravenous (IV) delivery, suggesting the absence of a skin depot. Only 10% of the desmopressin dose loaded onto the microneedle array was found on the skin surface after application. Additionally, the patches were well tolerated. These results suggest that transdermal delivery of desmopressin by Macroflux is a safe and efficient alternative to currently available routes of administration.
Subject(s)
Deamino Arginine Vasopressin/administration & dosage , Drug Delivery Systems/methods , Microinjections/methods , Administration, Cutaneous , Animals , Deamino Arginine Vasopressin/pharmacokinetics , Drug Delivery Systems/instrumentation , Female , Guinea Pigs , Male , Microinjections/instrumentationABSTRACT
PURPOSE: Fluid-bed spray-coating process is widely used to prepare non-protein pharmaceutical solid dosage forms using macro-size seed particles (200-1000 microm) at kilogram batch sizes. In this study we developed a small-scale fluid-bed spray-coating process (20 g) to produce micro-sized vaccine powder formulations (40-60 microm) for epidermal powder immunization (EPI) METHODS: A bench-top spray coater was used to spray two vaccines, diphtheria toxoid (dT) and alum-adsorbed hepatitis-B surface antigen (Alum-HBsAg), onto crystalline lactose particles of 40-60 microm in diameter. Particle properties such as particle size, surface morphology, and degree of particle agglomeration were determined. Protein stability was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The immunogenicity of the vaccine was evaluated in vivo by needle injection and epidermal powder immunization (EPI) of mice or guinea pigs. RESULTS: Coating feasibility was demonstrated for both vaccine formulations containing different excipients. However, the nature of the vaccine antigen appeared to affect coating feasibility in terms of particle agglomeration considerably. Delivery of spray-coated dT and alum-HBsAg through EPI to mice and guinea pigs, respectively, generated significant antibody responses, at a level comparable to liquid formulation delivered subcutaneously through needle/syringe injection. CONCLUSIONS: The new spray-coating process represents an important technical advance and may provide a useful tool for developing high-valued biopharmaceutical powder formulations for novel applications. The strong in vivo performance of the coated dT and alum-HBsAg powders by EPI further demonstrated that spray-coating is a viable dry powder formulation process and the skin's epidermal layer presents an efficient vaccine delivery route.
Subject(s)
Chemistry, Pharmaceutical , Powders , Animals , Excipients , Particle Size , VaccinesABSTRACT
PURPOSE: To develop stable and effective aluminum salt (alum)-adsorbed vaccine powder formulations for epidermal powder immunization (EPI) via a spray freeze-drying (SFD) process. METHODS: Powder properties were determined using particle size analysis, tap density, and scanning electron microscopy. Alum coagulation was monitored via optical microscopy and particle sedimentation. Protein analysis was determined by the BCA protein assay, SDS-PAGE, and an enzyme immunoassay. In vivo immunogenicity and skin reactogenicity were performed on hairless guinea pigs and pigs, respectively. RESULTS: SFD of hepatitis B surface antigen (HBsAg) adsorbed to aluminum hydroxide or aluminum phosphate using an excipient combination of trehalose/mannitol/dextran produced vaccine powders of dense particles and satisfactory powder flowability and hygroscopicity. This formulation also offered excellent long-term stability to the powder and the antigen. The two most important factors influencing alum particle coagulation are the freezing rate and the concentration of aluminum in the liquid formulation for SFD. The SFD vaccines, when delivered to hairless guinea pigs by EPI or injected intramuscularly after reconstitution, were as immunogenic as the original liquid vaccine. A further study showed that EPI with SFD alum-adsorbed diphtheria-tetanus toxoid vaccine was well tolerated, whereas needle injection of the liquid formulation caused persistent granuloma. CONCLUSIONS: Stabilization of alum-adsorbed vaccine by SFD has important implications in extending vaccination to areas lacking a cold chain for transportation and storage and may also accelerate the development of new immunization technologies such as EPI.